EGFR and breast carcinoma: Neratinib (Compound II, Figure 1) is a multi-targeting inhibitor of the EGFR family, which received FDA approval in 2017 for HER-2-positive breast cancer (Abourehab et al., 2021; Wu et al., 2023).